

**Supplementary Table 6: Clinical and pathologic characters in relation to progression free survival.**

	<b>median progression free survival (95% CI)</b>	<b>p value</b>
<b>Median PFS(95%CI)</b>	13(6.75-19.24)	
<b>Palbociclib</b>	13.67 (11.4-15.94)	0.63
<b>Ribociclib</b>	12.69(10.22-15.16)	
<b>Menopausal status in females</b>		<b>0.04</b>
Premenopausal	9(6.9-11)	
Postmenopausal	21(7-34.)	
<b>PS</b>		<b>0.005</b>
1	21(11.39-30.6)	
2	9(5.82-12.17)	
3	2.5(2.13-2.86)	
<b>Endocrine sensitivity</b>	All cases are censored	<b>0.026</b>
Sensitive		
Primary resistance		
Secondary resistance		
<b>Prior chemo</b>		0.342
No	17(10-24)	
Yes	9(3.64-14.85)	
<b>prior endocrine therapy status</b>		0.87
Tamofen	8(5.26-10.73)	
AI	21(4.5-37.5)	
Both	13(9.16-16.83)	
<b>Pathology grade</b>	All cases are censored	0.32
GI		
II		
III		
Lobular		
<b>HER2</b>		0.85
Negative	17(5.47-28.52)	
Low(+1 or +2 but ISH -ve)	13(8.69-17.3)	
<b>KI67</b>		0.39
≤20	21(4.88-37.12)	
>20	13(7.43-18.57)	
<b>Site of metastasis:</b>		<b>0.008</b>
Bone only	22(4-40)	
Visceral ± bone	10(6.68-13.31)	

**Supplementary Table 7: Relation between post treatment factors and progression free survival.**

	<b>Progression free survival(95% CI)</b>	<b>p</b>
<b>Need for dose reduction:</b>		
No	10(6.75-13.25)	<b>0.013</b>
Yes	21(4.17-37.83)	
<b>Site of progression</b>		
Bone	3.5( 2.42-4.57)	0.3
Visceral	6.5(3.9-9.1)	
Bone and visceral	3(2.44-3.55)	
<b>Subsequent line:</b>		
Chemo	5.75(2.81-8.68)	0.36
Everolimus	6.75(4.64-8.85)	

**Supplementary Table 8: Multivariate analysis for predictors of progression free survival.**

	$\beta$	p value	Hazard ratio (95%CI)
<b>Menopausal status</b>			
<b>Premenopausal (R )</b>		<b>0.004*</b>	1
<b>Post menopausal</b>	1.05		2.85(1.4-5.84)
<b>PS</b>			
<b>1 (R )</b>		<b>0.000</b>	1
<b>2</b>	-2.07	<b>0.000</b>	0.13(0.045-0.355)
<b>3</b>	-0.939	0.074	0.391(0.14-1.09)
<b>Need for dose reduction</b>			
<b>No (R )</b>		<b>0.044*</b>	1
<b>Yes</b>	1.21		3.36(1.03-10.97)

**Supplementary Table 9: Comparing of progression free survival between the 2 arms:**

	<b>Palbociclib median (95% CI)</b>	<b>Ribociclib median (95% CI)</b>	<b>P</b>
<b>Median PFS*</b>	13.67 (11.4-15.94)	12.69(10.22-15.16)	0.63
<b>Menopausal status</b>			
Premenopausal	9.25(5.61-12.88)	9(6.74-11.26)	<b>0.047</b>
Post menopausal	not reached	17(3.59-30.4)	
<b>Prior chemo</b>			
No	Not reached	17(6.54-27.45)	0.31
Yes	13	9(6.92-11.07)	
<b>KI67</b>			
≤20	Not reached	21(2.15-39.84)	0.27
>20	Not reached	13(7.32-18.67)	
<b>HER2</b>			
Negative	13	17(6.35-27.65)	0.61
Low(+1 or +2 but ISH -ve)	Not reached	10(4.67-15.32)	
<b>Site of metastasis:</b>			
Bone only	Not reached	22	0.73
Visceral ± bone	13	9.25(6.88-11.61)	



